Accueil / Tag Archives: Genetics

Tag Archives: Genetics

Extended Follow-Up Data Evaluating Opdivo (nivolumab) Shows Durable Response in Adult Patients with Relapsed or Progressed Classical Hodgkin Lymphoma

Friday, June 16th 2017 at 10:58am UTC Results show overall response rates of 65% or greater with median follow-up of at least 16 months, regardless of prior brentuximab vedotin therapies PRINCETON, N.J.–(BUSINESS WIRE)– Bristol-Myers Squibb Company (NYSE:BMY) today announced extended follow-up data in which Opdivo (nivolumab) demonstrated responses in adult …

Plus »

Dicerna Pharmaceuticals, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Thursday, June 15th 2017 at 11:30am UTC CAMBRIDGE, Mass.–(BUSINESS WIRE)– Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that based on recommendations from the Compensation Committee of the Company’s Board of Directors, on June 7, 2017, the Company’s Board of Directors …

Plus »

Bristol-Myers Squibb To Present New Research Related to the Treatment of Rheumatoid Arthritis Patients With Highly Active, Progressive Disease at the Annual European Congress of Rheumatology (EULAR 2017)

Wednesday, June 14th 2017 at 10:59am UTC Key analyses focus on treatment outcomes among RA patients with a traditionally poor prognosis ORENCIA® (abatacept) continuing research underscores Bristol-Myers Squibb’s commitment to advancing the science of modulating the body’s immune response to treat disease PRINCETON, N.J.–(BUSINESS WIRE)– Bristol-Myers Squibb Company (NYSE:BMY) today …

Plus »

LEO Science & Tech Hub Announce New Collaboration to Develop Technology for Minimally-Invasive Dermal Biomarker Assessment

Thursday, June 15th 2017 at 12:30pm UTC CAMBRIDGE, Mass.–(BUSINESS WIRE)– LEO Science & Tech Hub today announced a two-year collaboration with the Karp Lab at Brigham and Women’s Hospital (BWH) to develop minimally-invasive technology to advance dermal biomarker assessment. The Karp Lab, led by Jeffrey Karp, PhD, at BWH focuses …

Plus »

Humacyte® Selected as 2017 Technology Pioneer by World Economic Forum

Wednesday, June 14th 2017 at 5:00pm UTC Humacyte was selected for potential to significantly impact business and society through new technologies in regenerative medicine RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)– Humacyte, an innovator in biotechnology and regenerative medicine, was selected among hundreds of candidates as one of the World Economic Forum’s …

Plus »

Seattle Genetics and Bristol-Myers Squibb Highlight Interim Phase 1/2 Data Evaluating Combination of ADCETRIS® (Brentuximab Vedotin) and Opdivo® (Nivolumab) in Relapsed Hodgkin Lymphoma at the International Conference on Malignant Lymphoma

Thursday, June 15th 2017 at 10:58am UTC -Combination Data Show 85 Percent Objective Response Rate and 63 Percent Complete Response Rate with an Acceptable Safety Profile in these Pre-Transplant Relapsed or Refractory Classical Hodgkin Lymphoma Patients- -Data Support Recently Initiated Pivotal Phase 3 Clinical Trial Evaluating ADCETRIS and Opdivo Combination …

Plus »

Baxter Announces Agreement with Dorizoe Lifesciences to Further Expand Generic Injectables Pipeline

Wednesday, June 14th 2017 at 12:30pm UTC Collaboration builds upon Baxter’s pending acquisition of Claris and its ScinoPharm collaboration and advances Baxter’s strategy of becoming a leader in generic injectables DEERFIELD, Ill.–(BUSINESS WIRE)– Baxter International Inc. (NYSE: BAX), a global medical products company, today announced an agreement with Dorizoe Lifesciences …

Plus »

Intensity Therapeutics Issued New Patents for Technology Platform

Thursday, June 15th 2017 at 11:35am UTC US Patent 9,636,406 broadens existing claims for the Company’s proprietary technology Australia intends to grant the Company patent 2013318338 WESTPORT, Conn.–(BUSINESS WIRE)– Intensity Therapeutics, Inc., a privately held clinical-stage, biotechnology company developing proprietary cancer immunotherapy products, today announced that the United States Patent …

Plus »
Macbook Pro
* Intel Core i7 (3.8GHz, 6MB cache)
* Retina Display (2880 x 1880 px)
* NVIDIA GeForce GT 750M (Iris)
* 802.11ac Wi-Fi and Bluetooth 4.0
* Thunderbolt 2 (up to 20Gb/s)
* Faster All-Flash Storage (X1)
* Long Lasting Battery (9 hours)
Vous appréciez cet article ? Faites-nous part de vos commentaires.
Recevez nos alertes, nos dernières actualités, suivez-nous, enregistrez-vous gratuitement, rejoignez notre communauté. Merci à vous !
Increase more than 500% of Email Subscribers!
Your Information will never be shared with any third party.
Retrouvez nous sur
Un ensemble de solutions performantes
pour assurer le continuum de vos données.
All rights reserved © Company Name, 2014
Concours Genopole Young Biotech Award
* 100 000 € pour la meilleure Biotech
* Réservé aux biotechs hors santé
* 6 mois d'hébergement gratuit
* Un accompagnement personnalisé
* Etude de marché offerte
* Expertise du projet par EY
* Et nombre d'autres avantages...